Current therapeutic options leave many IBD patients wary of current treatments. Discover what new therapeutic approaches may be in the pipeline.
Your complimentary whitepaper on inflammatory bowel disease treatments answers the following questions:
• What are the current trends in sponsors and therapeutic classes?
• What drugs are the top competitors in IBD and how are they faring in clinical trials?
• How are the different sponsor types contributing to the IBD treatment paradigm?
Accurate and timely intelligence about the drug development pipeline is vital to understanding the opportunities and risks in today’s biopharmaceutical marketplace – whether you are targeting an unmet medical need, investigating promising new therapies or researching drug development historical trends and treatment patterns.